<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666562</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00906</org_study_id>
    <secondary_id>NCI-2009-00906</secondary_id>
    <secondary_id>CO06810</secondary_id>
    <secondary_id>CDR0000594276</secondary_id>
    <secondary_id>H-2007-0250</secondary_id>
    <secondary_id>UWI06-8-01</secondary_id>
    <secondary_id>UWI06-8-01</secondary_id>
    <secondary_id>N01CN35153</secondary_id>
    <secondary_id>P30CA014520</secondary_id>
    <nct_id>NCT00666562</nct_id>
  </id_info>
  <brief_title>Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer</brief_title>
  <official_title>A Phase II Randomized, Placebo-Controlled Trial of Polyphenon E to Evaluate Bladder Tissue Levels of EGCG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Green tea extract contains ingredients that may slow the growth of certain cancers. It is not
      yet known whether green tea extract is more effective than a placebo when given before
      surgery in treating patients with bladder. This randomized phase II trial is studying green
      tea extract to see how well it works compared to a placebo when given before surgery in
      treating patients with nonmetastatic bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES I. To compare the levels of epigallocatechin-3-gallate (EGCG) in
      nonmalignant bladder tissue from patients with bladder cancer treated with oral polyphenon E
      800 mg EGCG or polyphenon E 1200 mg EGCG once daily for 14-28 days.

      SECONDARY OBJECTIVES:

      I. To compare the levels of EGCG in nonmalignant versus malignant bladder tissue samples from
      these patients.

      II. To examine the dose-response modulation of surrogate intermediate endpoint biomarkers
      (e.g., Proliferating Cell Nuclear Antigen [PCNA], Matrix Metallopeptidase 2 [MMP2],
      clusterin, Vascular endothelial Growth Factor [VEGF], p27, and ODC) in malignant and
      nonmalignant samples of bladder tissue from these patients after administration of polyphenon
      E.

      III. To correlate EGCG levels in samples of serum, urine, and tissue from these patients.

      IV. To examine the levels of other catechins (i.e., epicatechin, epicatechin gallate, and
      epigallocatechin) found in polyphenon E in samples of serum, urine, and tissue from these
      patients.

      V. To compare the metabolism of EGCG by Catechol-O-Methyltransferase (COMT) and
      Uridinediphosphate-Glucuronosyltransferase (UGT) in relation to pharmacogenetic polymorphisms
      in COMT and UGT in samples of serum, urine, and tissue from these patients.

      VI. To examine the changes in serum Insulin Growth Factor 1 (IGF-1) and IGFBP-3 levels after
      administration of polyphenon E in these patients.

      OUTLINE:

      This is a multicenter study. Patients are stratified according to tumor site and disease
      invasiveness (invasive vs noninvasive). Patients are randomized to 1 of 3 treatment arms.

      Arm I: Patients receive six oral placebo capsules once daily for 14-28 days in the absence of
      unacceptable toxicity.

      Arm II: Patients receive four oral polyphenon E capsules and two oral placebo capsules once
      daily for 14-28 days in the absence of unacceptable toxicity.

      Arm III: Patients receive six oral polyphenon E capsules once daily for 14-28 days in the
      absence of unacceptable toxicity.

      After completion of study treatment, patients undergo trans-urethral resection of bladder
      tumor or cystectomy.

      Blood, urine, and tissue samples are obtained at baseline and at the end of study treatment
      for correlative laboratory studies. Samples are evaluated for pharmacokinetics of polyphenon
      E using high performance liquid chromatography. Levels of epigallocatechin-3-gallate [EGCG]
      and other catechins found in polyphenon E are assessed for correlation in serum, urine, and
      tissue. Intermediate endpoint biomarkers are evaluated for dose-response modulation in serum
      (i.e., IGF-1 and IGFBP-3) via ELISA and in bladder tissue obtained at the time of bladder
      surgery (i.e., PCNA, MMP2, clusterin, VEGF, p27, and ODS) via IHC. Patients at the University
      of Wisconsin undergo additional biopsy of bladder tissue for matrix-assisted laser desorption
      quadrupole time-of-flight (O-MALDI-qTOF) analysis of EGCG pharmacokinetics. Tissue samples
      are examined for intracellular concentration and distribution of EGCG. Genotyping studies for
      pyrosequencing of UGT and COMT polymorphisms are also performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2, 2008</start_date>
  <completion_date type="Actual">June 9, 2017</completion_date>
  <primary_completion_date type="Actual">April 26, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epigallocatechin Gallate (EGCG) Levels in Nonmalignant Bladder Tissue (e.g., Normal-appearing Urothelium, Inflammatory Lesions in the Bladder, Sessile Noninvasive Bladder Tumors, and Papillary Noninvasive Bladder Tumors)</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Comparison of nonmalignant bladder tissue levels of EGCG between the placebo group and the EGCG groups combined using student t-test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of EGCG in Malignant Bladder Tissue</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Surrogate Intermediate Endpoint Biomarkers in Malignant and Nonmalignant Bladder Tissue Assessed by Immunohistochemistry</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Insulin Growth Factor-1 (IGF-1) Levels Assessed by ELISA</measure>
    <time_frame>Baseline and up to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Other Catechins (Epicatechin Gallate, Epicatechin, and Epigallocatechin) Found in Polyphenon E Tumor Tissue Samples</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change for Baseline From EGCG in Serum Samples</measure>
    <time_frame>Baseline and up to 28 days</time_frame>
    <description>The difference between the amount at the end of study (up to 28 days) from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolism of EGCG in Serum and Urine in Relation to Pharmacogenetic Polymorphisms in Catechol-O-Methyltransferase (COMT)</measure>
    <time_frame>At Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IGFBP-3 Levels Assessed by ELISA</measure>
    <time_frame>Baseline and up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Other Catechins (Epicatechin Gallate, Epicatechin, and Epigallocatechin) Found in Polyphenon E Normal Tissue Samples</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline of Other Catechins (Epicatechin Gallate, Epicatechin, and Epigallocatechin) Found in Polyphenon E in Urine Samples</measure>
    <time_frame>Baseline and up to 28 days</time_frame>
    <description>The difference between the amount at the end of study (up to 28 days) from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline of Other Catechins (Epicatechin Gallate, Epicatechin, and Epigallocatechin) Found in Polyphenon E Plasma Samples</measure>
    <time_frame>Baseline and up to 28 days</time_frame>
    <description>The difference between the amount at the end of study (up to 28 days) from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change for Baseline of EGCG in Urine Samples</measure>
    <time_frame>Baseline and up to 28 days</time_frame>
    <description>The difference between the amount at the end of study (up to 28 days) from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolism of EGCG in Serum and Urine in Relation to Pharmacogenetic Polymorphisms in Uridinediphosphate- Glucuronosyltransferase (UGT)</measure>
    <time_frame>At Baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Stage I Bladder Cancer</condition>
  <condition>Stage II Bladder Cancer</condition>
  <condition>Stage III Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive six oral placebo capsules once daily for 14-28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (polyphenon E, placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive four oral polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (polyphenon E, trans-urethral resection or cystectomy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive six oral polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Defined Green Tea Catechin Extract</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II (polyphenon E, placebo)</arm_group_label>
    <arm_group_label>Arm III (polyphenon E, trans-urethral resection or cystectomy)</arm_group_label>
    <other_name>Polyphenon E</other_name>
    <other_name>Polyphenon E TM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (placebo)</arm_group_label>
    <arm_group_label>Arm II (polyphenon E, placebo)</arm_group_label>
    <arm_group_label>Arm III (polyphenon E, trans-urethral resection or cystectomy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (placebo)</arm_group_label>
    <arm_group_label>Arm II (polyphenon E, placebo)</arm_group_label>
    <arm_group_label>Arm III (polyphenon E, trans-urethral resection or cystectomy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (placebo)</arm_group_label>
    <arm_group_label>Arm II (polyphenon E, placebo)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Conventional Surgery</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Arm III (polyphenon E, trans-urethral resection or cystectomy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria:

          -  Diagnosis of bladder cancer

          -  Bladder tumor discovered on cystoscopy within the past 60 days

          -  Invasive or non-invasive tumor

          -  Primary tumor may represent either an initial diagnosis or recurrent disease of any
             clinical stage

          -  No metastatic disease

          -  Must be an eligible candidate for a partial cystectomy, radical cystectomy, or
             trans-urethral resection of bladder tumor (TURBT)

          -  Has not undergone any treatment for superficial or invasive bladder cancer since the
             diagnostic cystoscopy

          -  TURBT or radical cystectomy is the planned curative surgical treatment

          -  ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%

          -  More than 30 days since any prior intravesical therapy or adjuvant chemotherapy

          -  More than 30 days since prior bladder surgery

          -  Biopsies are not considered surgeries

          -  No prior pelvic radiotherapy

          -  No concurrent systemic chemotherapy for any other cancer, except nonmelanoma skin
             cancer

          -  No concurrent NSAIDs (e.g., ibuprofen, naproxen, or cyclooxygenase-2 inhibitors)
             except =&lt; 81 mg aspirin per day

          -  Concurrent acetaminophen (Tylenol) or prescription opioids combined with acetaminophen
             (i.e., Percocet, Darvocet, Vicodin, Tylenol #3) allowed for pain

          -  No other concurrent investigational agents

          -  White Blood Cell (WBC) &gt;= 3,000/mm^3

          -  Platelet count &gt;= 100,000/mm^3

          -  Hemoglobin &gt;= 10 g/dL

          -  Alkaline phosphatase =&lt; upper limit of normal (ULN)

          -  Bilirubin =&lt; ULN

          -  Asparate Aminotransferase (AST) and Alanine Transaminase (ALT) =&lt; ULN

          -  Sodium 135-144 mmol/L (inclusive)

          -  Potassium 3.2-4.8 mmol/L (inclusive)

          -  Chloride 85-114 mmol/L (inclusive)

          -  Bicarbonate &gt;11 mEQ/dL

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Willing to avoid green tea beverages and green tea-containing products during study
             participation

          -  No evidence of other cancers, except nonmelanoma skin cancer

          -  No history of allergic reactions attributed to tea or to any of the compounds of
             similar chemical or biologic composition to Polyphenon E or any of the inactive
             ingredients in Polyphenon E capsules

          -  No uncontrolled intercurrent illness including, but not limited to, any of the
             following: Ongoing or active infection, Symptomatic congestive heart failure, Unstable
             angina pectoris, Cardiac arrhythmia, Psychiatric illness/social situations that would
             limit study compliance

          -  More than 24 hours since prior and no concurrent consumption of any other green tea
             supplements or more than 2 cups (16 oz) of green tea either through dietary sources or
             through nutritional supplementation

          -  Topical cosmetics (i.e., lotions, shampoos, makeup) that contain green tea are allowed

          -  Creatinine normal

          -  Not pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tracy Downs</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital and Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Veterans Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio Research PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2008</study_first_posted>
  <results_first_submitted>January 20, 2016</results_first_submitted>
  <results_first_submitted_qc>February 24, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 28, 2016</results_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epigallocatechin gallate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited during a 4 year period by staff at 5 participating institutions (both University hospitals and community clinics).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Placebo)</title>
          <description>Patients receive six oral placebo capsules once daily for 14-28 days. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="P2">
          <title>Arm II (800mg Polyphenon E, Placebo)</title>
          <description>Patients receive four oral 800mg polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="P3">
          <title>Arm III (1200mg Polyphenon E)</title>
          <description>Patients receive six oral 1200mg polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
therapeutic conventional surgery: Undergo surgery
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Concomitant Medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Placebo)</title>
          <description>Patients receive six oral placebo capsules once daily for 14-28 days. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="B2">
          <title>Arm II (800mg Polyphenon E, Placebo)</title>
          <description>Patients receive four oral 800mg polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="B3">
          <title>Arm III (1200mg Polyphenon E)</title>
          <description>Patients receive six oral 1200mg polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
therapeutic conventional surgery: Undergo surgery
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.00" spread="7.04"/>
                    <measurement group_id="B2" value="65.20" spread="9.50"/>
                    <measurement group_id="B3" value="66.20" spread="9.55"/>
                    <measurement group_id="B4" value="67.23" spread="8.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Epigallocatechin Gallate (EGCG) Levels in Nonmalignant Bladder Tissue (e.g., Normal-appearing Urothelium, Inflammatory Lesions in the Bladder, Sessile Noninvasive Bladder Tumors, and Papillary Noninvasive Bladder Tumors)</title>
        <description>Comparison of nonmalignant bladder tissue levels of EGCG between the placebo group and the EGCG groups combined using student t-test.</description>
        <time_frame>up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Placebo)</title>
            <description>Patients receive six oral placebo capsules once daily for 14-28 days. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (800mg Polyphenon E, Placebo)</title>
            <description>Patients receive four oral 800mg polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Arm III (1200mg Polyphenon E)</title>
            <description>Patients receive six oral 1200mg polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
therapeutic conventional surgery: Undergo surgery
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Epigallocatechin Gallate (EGCG) Levels in Nonmalignant Bladder Tissue (e.g., Normal-appearing Urothelium, Inflammatory Lesions in the Bladder, Sessile Noninvasive Bladder Tumors, and Papillary Noninvasive Bladder Tumors)</title>
          <description>Comparison of nonmalignant bladder tissue levels of EGCG between the placebo group and the EGCG groups combined using student t-test.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.50" spread="1.42"/>
                    <measurement group_id="O3" value="1.72" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.046</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of EGCG in Malignant Bladder Tissue</title>
        <time_frame>up to 28 days</time_frame>
        <population>Analysis was not able to be completed for 1 participant in Arm I, 1 participant in Arm II, and 3 participants in Arm III.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Placebo)</title>
            <description>Patients receive six oral placebo capsules once daily for 14-28 days. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (800mg Polyphenon E, Placebo)</title>
            <description>Patients receive four oral 800mg polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Arm III (1200mg Polyphenon E)</title>
            <description>Patients receive six oral 1200mg polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
therapeutic conventional surgery: Undergo surgery
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of EGCG in Malignant Bladder Tissue</title>
          <population>Analysis was not able to be completed for 1 participant in Arm I, 1 participant in Arm II, and 3 participants in Arm III.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="2.54" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Surrogate Intermediate Endpoint Biomarkers in Malignant and Nonmalignant Bladder Tissue Assessed by Immunohistochemistry</title>
        <time_frame>up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Placebo)</title>
            <description>Patients receive six oral placebo capsules once daily for 14-28 days. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (800mg Polyphenon E, Placebo)</title>
            <description>Patients receive four oral 800mg polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Arm III (1200mg Polyphenon E)</title>
            <description>Patients receive six oral 1200mg polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
therapeutic conventional surgery: Undergo surgery
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Surrogate Intermediate Endpoint Biomarkers in Malignant and Nonmalignant Bladder Tissue Assessed by Immunohistochemistry</title>
          <units>optical density</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCNA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.052"/>
                    <measurement group_id="O2" value="0.38" spread="0.061"/>
                    <measurement group_id="O3" value="0.35" spread="0.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.026"/>
                    <measurement group_id="O2" value="0.18" spread="0.054"/>
                    <measurement group_id="O3" value="0.16" spread="0.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clusterin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.074" spread="0.032"/>
                    <measurement group_id="O2" value="0.061" spread="0.020"/>
                    <measurement group_id="O3" value="0.046" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.011" spread="0.0065"/>
                    <measurement group_id="O2" value="0.021" spread="0.0173"/>
                    <measurement group_id="O3" value="0.013" spread="0.0066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.080"/>
                    <measurement group_id="O2" value="0.35" spread="0.090"/>
                    <measurement group_id="O3" value="0.31" spread="0.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Insulin Growth Factor-1 (IGF-1) Levels Assessed by ELISA</title>
        <time_frame>Baseline and up to day 28</time_frame>
        <population>Analysis was not able to be completed for 2 participants in Arm I.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Placebo)</title>
            <description>Patients receive six oral placebo capsules once daily for 14-28 days. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (800mg Polyphenon E, Placebo)</title>
            <description>Patients receive four oral 800mg polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Arm III (1200mg Polyphenon E)</title>
            <description>Patients receive six oral 1200mg polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
therapeutic conventional surgery: Undergo surgery
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Insulin Growth Factor-1 (IGF-1) Levels Assessed by ELISA</title>
          <population>Analysis was not able to be completed for 2 participants in Arm I.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.06" spread="22.64"/>
                    <measurement group_id="O2" value="122.22" spread="37.49"/>
                    <measurement group_id="O3" value="132.12" spread="15.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.86" spread="15.59"/>
                    <measurement group_id="O2" value="124.22" spread="38.06"/>
                    <measurement group_id="O3" value="132.27" spread="27.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Other Catechins (Epicatechin Gallate, Epicatechin, and Epigallocatechin) Found in Polyphenon E Tumor Tissue Samples</title>
        <time_frame>up to 28 days</time_frame>
        <population>Analysis was not able to be completed for 1 participant in Arm I, 1 participant in Arm II, and 3 participants in Arm III.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Placebo)</title>
            <description>Patients receive six oral placebo capsules once daily for 14-28 days. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (800mg Polyphenon E, Placebo)</title>
            <description>Patients receive four oral 800mg polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Arm III (1200mg Polyphenon E)</title>
            <description>Patients receive six oral 1200mg polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
therapeutic conventional surgery: Undergo surgery
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Other Catechins (Epicatechin Gallate, Epicatechin, and Epigallocatechin) Found in Polyphenon E Tumor Tissue Samples</title>
          <population>Analysis was not able to be completed for 1 participant in Arm I, 1 participant in Arm II, and 3 participants in Arm III.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>epicatechin gallate (ECG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>epicatechin (EC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>epigallocatechin (EGC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.60" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change for Baseline From EGCG in Serum Samples</title>
        <description>The difference between the amount at the end of study (up to 28 days) from baseline.</description>
        <time_frame>Baseline and up to 28 days</time_frame>
        <population>Analysis was not able to be completed for 2 participants in Arm I and 1 participant in Arm II.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Placebo)</title>
            <description>Patients receive six oral placebo capsules once daily for 14-28 days. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (800mg Polyphenon E, Placebo)</title>
            <description>Patients receive four oral 800mg polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Arm III (1200mg Polyphenon E)</title>
            <description>Patients receive six oral 1200mg polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
therapeutic conventional surgery: Undergo surgery
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change for Baseline From EGCG in Serum Samples</title>
          <description>The difference between the amount at the end of study (up to 28 days) from baseline.</description>
          <population>Analysis was not able to be completed for 2 participants in Arm I and 1 participant in Arm II.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="1.11"/>
                    <measurement group_id="O2" value="82.33" spread="83.66"/>
                    <measurement group_id="O3" value="85.37" spread="76.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolism of EGCG in Serum and Urine in Relation to Pharmacogenetic Polymorphisms in Catechol-O-Methyltransferase (COMT)</title>
        <time_frame>At Baseline</time_frame>
        <population>This outcome was assessed in all participants,combined irrespective of their randomization.
Analysis was not able to be completed on 4 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycine/Glycine</title>
            <description>G to G transition in the COMT gene</description>
          </group>
          <group group_id="O2">
            <title>Alanine/Glycine</title>
            <description>A to G transition in the COMT gene</description>
          </group>
          <group group_id="O3">
            <title>Alanine/Alanine</title>
            <description>A to A transition in the COMT gene</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolism of EGCG in Serum and Urine in Relation to Pharmacogenetic Polymorphisms in Catechol-O-Methyltransferase (COMT)</title>
          <population>This outcome was assessed in all participants,combined irrespective of their randomization.
Analysis was not able to be completed on 4 participants.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.12" spread="4.80"/>
                    <measurement group_id="O2" value="0.57" spread="1.89"/>
                    <measurement group_id="O3" value="2.48" spread="3.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.69" spread="1.82"/>
                    <measurement group_id="O3" value="0.43" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum IGFBP-3 Levels Assessed by ELISA</title>
        <time_frame>Baseline and up to 28 days</time_frame>
        <population>Analysis was not able to be completed for 2 participants in Arm I.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Placebo)</title>
            <description>Patients receive six oral placebo capsules once daily for 14-28 days. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (800mg Polyphenon E, Placebo)</title>
            <description>Patients receive four oral 800mg polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Arm III (1200mg Polyphenon E)</title>
            <description>Patients receive six oral 1200mg polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
therapeutic conventional surgery: Undergo surgery
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Serum IGFBP-3 Levels Assessed by ELISA</title>
          <population>Analysis was not able to be completed for 2 participants in Arm I.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1918.31" spread="607.16"/>
                    <measurement group_id="O2" value="1679.61" spread="556.59"/>
                    <measurement group_id="O3" value="1824.86" spread="559.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2020.31" spread="701.46"/>
                    <measurement group_id="O2" value="1800.08" spread="490.92"/>
                    <measurement group_id="O3" value="1624.03" spread="611.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Other Catechins (Epicatechin Gallate, Epicatechin, and Epigallocatechin) Found in Polyphenon E Normal Tissue Samples</title>
        <time_frame>up to 28 days</time_frame>
        <population>Analysis was not able to be completed for 2 participants in Arm I and 2 participants in Arm III.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Placebo)</title>
            <description>Patients receive six oral placebo capsules once daily for 14-28 days. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (800mg Polyphenon E, Placebo)</title>
            <description>Patients receive four oral 800mg polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Arm III (1200mg Polyphenon E)</title>
            <description>Patients receive six oral 1200mg polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
therapeutic conventional surgery: Undergo surgery
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Other Catechins (Epicatechin Gallate, Epicatechin, and Epigallocatechin) Found in Polyphenon E Normal Tissue Samples</title>
          <population>Analysis was not able to be completed for 2 participants in Arm I and 2 participants in Arm III.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>epicatechin gallate (ECG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>epicatechin (EC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.20" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>epigallocatechin (EGC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.20" spread="0.55"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline of Other Catechins (Epicatechin Gallate, Epicatechin, and Epigallocatechin) Found in Polyphenon E in Urine Samples</title>
        <description>The difference between the amount at the end of study (up to 28 days) from baseline.</description>
        <time_frame>Baseline and up to 28 days</time_frame>
        <population>Analysis was not able to be completed for 3 participants in Arm I and 1 participant in Arm II.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Placebo)</title>
            <description>Patients receive six oral placebo capsules once daily for 14-28 days. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (800mg Polyphenon E, Placebo)</title>
            <description>Patients receive four oral 800mg polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Arm III (1200mg Polyphenon E)</title>
            <description>Patients receive six oral 1200mg polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
therapeutic conventional surgery: Undergo surgery
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline of Other Catechins (Epicatechin Gallate, Epicatechin, and Epigallocatechin) Found in Polyphenon E in Urine Samples</title>
          <description>The difference between the amount at the end of study (up to 28 days) from baseline.</description>
          <population>Analysis was not able to be completed for 3 participants in Arm I and 1 participant in Arm II.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>epicatechin gallate (ECG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="1.13" spread="1.78"/>
                    <measurement group_id="O3" value="1.49" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>epicatechin (EC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="1.46"/>
                    <measurement group_id="O2" value="2.41" spread="3.15"/>
                    <measurement group_id="O3" value="5.33" spread="6.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epigallocatechin (EGC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.55"/>
                    <measurement group_id="O2" value="3.60" spread="3.21"/>
                    <measurement group_id="O3" value="12.16" spread="11.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline of Other Catechins (Epicatechin Gallate, Epicatechin, and Epigallocatechin) Found in Polyphenon E Plasma Samples</title>
        <description>The difference between the amount at the end of study (up to 28 days) from baseline.</description>
        <time_frame>Baseline and up to 28 days</time_frame>
        <population>Analysis was not able to be completed for 2 participants in Arm I and 1 participant in Arm II.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Placebo)</title>
            <description>Patients receive six oral placebo capsules once daily for 14-28 days. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (800mg Polyphenon E, Placebo)</title>
            <description>Patients receive four oral 800mg polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Arm III (1200mg Polyphenon E)</title>
            <description>Patients receive six oral 1200mg polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
therapeutic conventional surgery: Undergo surgery
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline of Other Catechins (Epicatechin Gallate, Epicatechin, and Epigallocatechin) Found in Polyphenon E Plasma Samples</title>
          <description>The difference between the amount at the end of study (up to 28 days) from baseline.</description>
          <population>Analysis was not able to be completed for 2 participants in Arm I and 1 participant in Arm II.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>epicatechin gallate (ECG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.52"/>
                    <measurement group_id="O2" value="8.38" spread="11.03"/>
                    <measurement group_id="O3" value="8.62" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>epicatechin (EC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.97" spread="1.97"/>
                    <measurement group_id="O3" value="0.31" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>epigallocatechin (EGC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="6.93" spread="10.06"/>
                    <measurement group_id="O3" value="3.46" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change for Baseline of EGCG in Urine Samples</title>
        <description>The difference between the amount at the end of study (up to 28 days) from baseline.</description>
        <time_frame>Baseline and up to 28 days</time_frame>
        <population>Analysis was not able to be completed for 3 participants in Arm I and 1 participant in Arm II.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Placebo)</title>
            <description>Patients receive six oral placebo capsules once daily for 14-28 days. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (800mg Polyphenon E, Placebo)</title>
            <description>Patients receive four oral 800mg polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Arm III (1200mg Polyphenon E)</title>
            <description>Patients receive six oral 1200mg polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
therapeutic conventional surgery: Undergo surgery
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change for Baseline of EGCG in Urine Samples</title>
          <description>The difference between the amount at the end of study (up to 28 days) from baseline.</description>
          <population>Analysis was not able to be completed for 3 participants in Arm I and 1 participant in Arm II.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="1.93" spread="0.98"/>
                    <measurement group_id="O3" value="3.38" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolism of EGCG in Serum and Urine in Relation to Pharmacogenetic Polymorphisms in Uridinediphosphate- Glucuronosyltransferase (UGT)</title>
        <time_frame>At Baseline</time_frame>
        <population>This outcome was assessed in all participants,combined irrespective of their randomization. Analysis was not able to be completed for 4 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>5/6 Genotype</title>
            <description>Genotype of the UGT in EGCG</description>
          </group>
          <group group_id="O2">
            <title>6/6 Genotype</title>
            <description>Genotype of the UGT in EGCG</description>
          </group>
          <group group_id="O3">
            <title>6/7 Genotype</title>
            <description>Genotype of the UGT in EGCG</description>
          </group>
          <group group_id="O4">
            <title>7/7 Genotype</title>
            <description>Genotype of the UGT in EGCG</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolism of EGCG in Serum and Urine in Relation to Pharmacogenetic Polymorphisms in Uridinediphosphate- Glucuronosyltransferase (UGT)</title>
          <population>This outcome was assessed in all participants,combined irrespective of their randomization. Analysis was not able to be completed for 4 participants.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97" spread="4.20"/>
                    <measurement group_id="O2" value="2.09" spread="3.75"/>
                    <measurement group_id="O3" value="2.02" spread="3.58"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="2.43"/>
                    <measurement group_id="O2" value="0.86" spread="2.27"/>
                    <measurement group_id="O3" value="0.10" spread="0.40"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Placebo)</title>
          <description>Patients receive six oral placebo capsules once daily for 14-28 days. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="E2">
          <title>Arm II (800mg Polyphenon E, Placebo)</title>
          <description>Patients receive four oral 800mg polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
placebo: Given orally
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="E3">
          <title>Arm III (1200mg Polyphenon E)</title>
          <description>Patients receive six oral 1200mg polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
defined green tea catechin extract: Given orally
therapeutic conventional surgery: Undergo surgery
pharmacological study: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>heartburn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>taste alteration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>anal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>imb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>extremity limb pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>joint pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>muscle pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>pelvis pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>kidney pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Howard H. Bailey</name_or_title>
      <organization>University of Wisconsin</organization>
      <phone>608-263-8624</phone>
      <email>hhbailey@wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

